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ABSTRACT
In an ongoing effort to identify molecular determinants regulating melanoma 
brain metastasis, we previously identified Angiopoietin-like 4 (ANGPTL4) as a 
component of the molecular signature of such metastases.
The aim of this study was to determine the functional significance of ANGPTL4 
in the shaping of melanoma malignancy phenotype, especially in the establishment 
of brain metastasis. 
We confirmed that ANGPTL4 expression is significantly higher in cells 
metastasizing to the brain than in cells from the cutaneous (local) tumor from 
the same melanoma in a nude mouse xenograft model, and also in paired clinical 
specimens of melanoma metastases than in primary melanomas from the same 
patients.
In vitro experiments indicated that brain-derived soluble factors and transforming 
growth factor β1 (TGFβ1) up-regulated ANGPTL4 expression by melanoma cells.
Forced over-expression of ANGPTL4 in cutaneous melanoma cells promoted their 
ability to adhere and transmigrate brain endothelial cells. Over-expressing ANGPTL4 
in cells derived from brain metastases resulted in the opposite effects.
In vivo data indicated that forced overexpression of ANGPTL4 promoted the 
tumorigenicity of cutaneous melanoma cells but did not increase their ability to form 
brain metastasis. This finding can be explained by inhibitory activities of brain-derived 
soluble factors.
Taken together these findings indicate that ANGPTL4 promotes the malignancy 
phenotype of primary melanomas of risk to metastasize to the brain.
INTRODUCTION
Malignant melanoma has a high tendency to develop 
brain metastasis [1], conferring upon melanoma patients a 
very poor prognosis [2]. As disease management improves 
and the survival of melanoma patients is prolonged, the 
number of patients that eventually develop clinical brain 
metastasis increases. Treatment options are limited beyond 
surgery [3] and survival of treated patients depends on 
tumor size, metastasis location, and number of tumor 
metastasis [3]. 
The brain microenvironment consists of several 
resident cell types: endothelial cells, astrocytes, microglia, 
and neurons. To develop brain metastasis, melanoma cells 
must reach the brain vasculature, attach to endothelial 
cells covering the microvessel walls, extravasate the brain 
endothelium and invade the brain parenchyma, proliferate 
and induce angiogenesis [4]. Interactions with brain 
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microenvironmental cells facilitate metastasis formation. 
Astrocytes, for example, interact with tumor cells in the 
brain whereby, these interactions may promote metastasis 
growth [5, 6]. Furthermore, interaction of glioma initiating 
cells with macrophages/microglia up-regulate B7-H4 
expression in the latter cells, blocking effective T-cell 
immune responses [7]. The molecules and mechanisms 
involved in the interactions between melanoma cells and 
normal brain microenvironment cells have not been fully 
characterized.
We developed human melanoma xenograft models 
encompassing cutaneous (local tumor) and melanoma 
brain metastasis (MBM) variants originating from single 
melanoma tumors [8]. These models have 2 major tumor 
biologic relevancies: 1. Both types of variants share a 
common genetic background. 2. MBM cells originate 
from cells exposed initially to the microenvironment of 
the primary tumor and subsequently to the metastatic 
microenvironment of the brain while the cutaneous 
variants experienced the former microenvironment. This 
model enables thus to dissect melanoma characteristics 
that were influenced by the microenvironment of the local 
cutaneous tumor from those conferred by the metastatic 
microenvironment.
Previous experiments using these models indicated 
that several genes such as ANGPTL4, CCR4, PTGS2, 
MMP1, and PRAME are more highly expressed by human 
MBM cells than by the respective cutaneous variants. 
Other genes such as ITGA4, CLDN1, CYR61, CDH1, and 
IL6R are aberrantly down-regulated in brain metastases 
[8, 9]. Our functional studies indicated that claudin-1 
(CLDN1) is a MBM suppressor [10] and recently that 
CCR4 is a MBM promoter [11]. 
Angiopoietin-like 4 (ANGPTL4) is a secreted 
cytokine member of the angiopoietin family of vascular 
regulators [12]. Angiopoietin-like proteins take part in 
endothelial cell survival, adhesion and paradoxically, 
stimulation or inhibition of angiogenesis and vascular 
leakiness [12, 13]. 
ANGPTL4 acts as a tumor suppressor or promoter 
of cancer metastasis, depending on cell type and stage 
of cancer [14]. ANGPTL4 regulates diverse malignant 
processes. It disrupts vascular endothelial cell-cell 
tight junctions (TJ) and adherence junctions, facilitates 
trans-endothelial passage of tumor cells, regulates cell 
proliferation, apoptosis, angiogenesis, adhesion, motility 
and wound healing and acts as an immunosuppressive 
factor [12, 15]. ANGPTL4 is also correlated with brain 
metastasis relapse in breast cancer [16]. However, some 
studies demonstrated the opposite effects [17].
A further investigation is needed using our brain 
metastasis model to better understand how the tumor 
microenvironment influences the function of ANGPTL4 
in early stages of MBM.
RESULTS
Brain metastasizing melanoma variants over-
express ANGPTL4
In a previous study we showed that MBM variants 
of 3 different human melanoma xenograft models express 
higher levels of ANGPTL4 than their corresponding 
cutaneous variants [8]. These findings were confirmed 
in three additional independent melanoma models: by 
using Western blot analysis, we assessed ANGPTL4 
expression in cutaneous and MBM cells of the parental 
human melanoma cells UCLA-SO-M12, UCLA-SO-M16, 
and DP-0574-Me. A significant higher expression of 
ANGPTL4 was observed in the brain macro-metastatic 
variants of these melanomas than in the corresponding 
cutaneous variants (P < 0.05) (Figure 1A). Remarkably, 
we also identified that ANGPTL4 is up-regulated in 
MBM clinical samples. The expression of ANGPTL4 
was measured in a cohort of 12 melanoma patients with 
paired primary melanoma (PRM), melanoma lymph node 
metastasis (LNM), and MBM. Autologous paired triplets 
(PRM; LNM; MBM) were derived from 8 patients, paired 
duplets (PRM-LNM) or (LNM-MBM) were derived from 
3 patients and a single MBM was derived from one patient. 
Immunohistochemistry (IHC) staining indicated that LNM 
and MBM exhibited significantly higher expression of 
ANGPTL4 (P < 0.005 and P < 0.0005, respectively) than 
paired PRM, and that MBM exhibited significantly (P < 
0.01) higher expression of ANGPTL4 than paired LNM 
(Figure 1B, 1C).
ANGPTL4 expression is up-regulated by tumor 
growth factor β1 (TGFβ1)
Melanoma cells can secrete high amounts of 
TGFβ1, inducing its own expression through a positive 
feedback loop [18]. Elevated TGFβ1 plasma levels 
have been shown to correlate with melanoma metastatic 
progression whereby, this cytokine is known to promote 
tumor progression [19]. The TGFβ1 signaling axis 
regulates the expression of a variety of genes such as 
cytokines, angiogenic factors, extracellular matrix (ECM) 
components and cell-surface receptors [12].
We tested whether TGFβ1 regulates ANGPTL4 
in cutaneous and MBM cells. Melanoma cells were 
stimulated with 5ng/ml TGFβ1 for 4 hrs. Respective 
control cells remained untreated. Reverse transcription 
quantitative real-time PCR (RT-qPCR) analysis was 
performed to determine ANGPTL4 mRNA expression 
level. The results showed that TGFβ1 significantly up-
regulated ANGPTL4 expression in both the cutaneous 
and MBM cells (P < 0.05) (Figure 1D). ANGPTL4 up-
regulation in cutaneous and MBM cells was confirmed at 
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Figure 1: ANGPTL4 expression during melanoma progression to brain metastasis. A. ANGPTL4 protein expression level 
in UCLA-SO-M12, UCLA-SO-M16 and DP-0574-Me cutaneous (CUT) and melanoma brain metastasizing (MBM) variants of first and 
second IC inoculation cycle was analyzed using Western blotting. The obtained values were normalized to β-Tubulin. The bars represent the 
relative expression of ANGPTL4 (normalized to RS9), compared to control, untreated cells + SD obtained in one measurement in at least 
three independent experiments. *P < 0.05. B., C. ANGPTL4 expression in paired samples of primary melanoma (PRM), melanoma lymph 
node metastasis (LNM), and melanoma brain metastasis (MBM) derived from melanoma patients. (B) Representative IHC staining with 
anti-ANGPTL4 Ab for PRM, LNM and MBM specimens. Black bars indicate 100µm. The insets show a magnification of the melanoma 
lesions. Black arrowheads indicate ANGPTL4 positive melanoma cells. Yellow bars indicate 20µm. (C) Box plot comparing H score 
for PRM, LNM and MBM. *P < 0.01, **P < 0.005, ***P < 0.0005. D. Melanoma cells were incubated with 5ng/ml TGFβ1 for 4 hrs. 
Following stimulation, RT-qPCR analysis was performed to determine the mRNA expression level of ANGPTL4. The bars represent the 
relative expression of ANGPTL4 (normalized to RS9), compared to control, untreated cells + SD obtained in one measurement in at least 
three independent experiments. *P < 0.05. E. Brains of BALB/c mice were harvested, and BDF were prepared after 24 hrs (see Materials 
and Methods) and added to melanoma cells for 24 hrs at 37°C. Melanoma cells treated with 0.5% BSA supplemented RPMI-1640 served as 
control. Following stimulation, RT-qPCR analysis was performed to determine the mRNA expression level of ANGPTL4. The bars represent 
the relative expression of ANGPTL4 (normalized to RS9), compared to control, untreated cells + SEM obtained in one measurement in 
at least three independent experiments. *P < 0.05. F., G. CM of microglia (MG), astrocytes (HA) and BEC was collected, and added to 
YDFR.CB3 (F) and DP.CB2 (G) melanoma cells for 24 hrs at 37°C. Melanoma cells treated with starvation medium served as control. 
Following stimulation, RT-qPCR analysis was performed to determine the mRNA expression level of ANGPTL4. The bars represent the 
relative expression of ANGPTL4 (normalized to RS9), compared to control, untreated cells + SEM obtained in one measurement in at least 
three independent experiments. *P < 0.05, **P < 0.005. 
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Figure 2: ANGPTL4 controls the malignancy phenotype of cutaneous and brain metastasizing melanoma variants. A.-
C. Cutaneous (CUT) and melanoma brain metastasizing (MBM) variants were transduced with an ANGPTL4 cDNA-containing construct 
(ANGPTL4hi) or with the backbone construct pQCXIP (CONpQC). MBM cells were transduced with a mixture of 4 different shANGPTL4-
containing constructs (ANGPTL4lo), or with the control construct (CONsh). The efficacy of ANGPTL4 over-expression or down-regulation 
was verified: (A) RT-qPCR analysis was performed to determine the mRNA expression level of ANGPTL4. The bars represent the 
relative ANGPTL4 expression (normalized to RS9) in ANGPTL4hi or ANGPTL4lo cells compared to control cells + SEM obtained in one 
measurement in at least three independent experiments. *P < 0.05. (B, C) Supernatants of the transduced cells were subjected to Western 
blot analysis. ANGPTL4 was detected by specific Abs. The bars represent the relative ANGPTL4 expression in ANGPTL4hi or ANGPTL4lo 
cells compared to control cells + SEM obtained in one measurement in two-three independent experiments. *P < 0.05. Representative 
blots are shown. Ponceau staining was used for loading control. D., E. Melanoma cells were allowed to migrate through collagen coated 
transwells for 24 hrs. The migrated cells were fixed and counted. (D) Representative images are presented (X10 magnification). (E) The 
bars represent the average number of migrating cells per field in three independent experiments performed in triplicates + SEM. *P < 0.05. 
F. BEC were cultured for 24 hrs to form a confluent monolayer and stimulated with 100 units/ml TNFα and IFNγ for additional 24 hrs. 
mCherry- or GFP-expressing melanoma cells were added and allowed to adhere for 30 min at 37°C. The fluorescence signal of labeled 
cells was measured before and after removal of non-adherent cells. The bars represent the average % adherent cells (normalized to control 
cells) + SEM in at least three independent experiments. Six replicates were performed in each experiment. *P < 0.05. G.-I. BEC were 
cultured for 48 hrs on the upper side of the apical chamber of transwell inserts to form a confluent monolayer. Astrocytes were cultured in 
24-well plates for 24 hrs and starved for additional 24 hrs to allow the secretion of soluble factors. mCherry-expressing melanoma cells 
were added onto the BEC monolayer and allowed to migrate for 24 hrs towards the astrocytes (G). The migrated cells were fixed and 
counted. (H) Representative images are presented (X10 magnification). (I) The bars represent the average number of migrating cells per 
field (normalized to control cells) in at least three independent experiments performed in triplicates + SEM. *P < 0.05. 
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the protein level after a 24 hrs treatment (in a fold change 
of 3.16 and 1.34, respectively) and after a 48 hrs treatment 
(in a fold change of 3.59 and 2.8, respectively) with 5ng/
ml TGFβ1, compared to control, untreated cells. 
ANGPTL4 expression is up-regulated by brain-
derived factors (BDF)
In order to test whether the brain microenvironment 
modulates the expression of ANGPTL4 in melanoma cells, 
melanoma cells were subjected to BDF (see Materials 
and Methods) for 24 hrs, and then tested for ANGPTL4 
expression. In Figure 1E we demonstrated that BDF 
significantly up-regulated the expression of ANGPTL4, 
compared to its expression in respective control cells 
(P < 0.05). ANGPTL4 up-regulation in YDFR.CB3 and 
DP.CB2 cells was confirmed at the protein level after a 
48 hrs treatment with BDF (in a fold change of 1.5 and 
1.46, respectively), compared to control, untreated cells. 
In order to examine which cells of the normal brain 
environment are the source of the soluble products that 
up-regulate ANGPTL4 expression, we performed similar 
experiments with conditioned medium (CM) of microglia, 
astrocytes, and brain endothelial cells (BEC). Figure 1F 
showed that soluble factors of these three cells increased 
ANGPTL4 expression in YDFR.CB3 cells (P < 0.05). In 
addition, in figure 1G it was demonstrated that soluble 
factors of microglia and BEC increased ANGPTL4 
expression in DP.CB2 melanoma cells (P < 0.05). 
Overexpression or knockdown of ANGPTL4 in 
melanoma cells
Cutaneous and MBM cells were infected with 
virions composed of constructs containing ANGPTL4 
cDNA, to establish cell populations over-expressing 
ANGPTL4 (ANGPTL4hi cells). The same cells, infected 
with virions containing a mock plasmid, were used as 
control (CONpQC). Over-expression of ANGPTL4 was 
validated using both RT-qPCR and Western blotting 
(Figure 2A, 2B). To down-regulate endogenous ANGPTL4 
expression, we infected MBM cells with virions containing 
a mixture of four different shANGPTL4-pGIPZ plasmids 
(ANGPTL4lo). 
Using RT-qPCR and Western blotting we examined 
these four plasmids for their efficacy to down-regulate the 
expression of this protein (data not shown). A mixture of 
the four vectors was used to maximize ANGPTL4 knock 
down as it showed the strongest effect (Figure 2A, 2C).
The same cells, infected with virions containing sh-
non-silencing pGIPZ vector, were used as control (CONsh). 
ANGPTL4 regulates the migratory capacity of 
melanoma cells
The invasion of cancer cells into surrounding 
tissues as well as their intravasation and extravasation 
requires migration steered by protrusive activity of the 
cell membrane and its attachment to the ECM [20]. Since 
ANGPTL4 alters the migratory capacity of several cell 
types [13, 21], we examined if ANGPTL4 over-expressing 
melanoma cells would manifest an altered ability to 
migrate through collagen coated transwells. Cutaneous 
ANGPTL4hi cells migrated more efficiently than the 
corresponding CONpQC cells (P < 0.05) (Figure 2D, 2E). In 
contrast, ANGPTL4hi MBM cells migrated less efficiently 
than the corresponding CONpQC cells (P < 0.05). 
We also examined if ANGPTL4 down-regulation 
alters the ability of melanoma cells to migrate through 
collagen coated transwells. The results indicated that 
ANGPTL4 knock down in MBM cells does not affect 
these tumor cells migratory and invasion ability (Figure 
2D, 2E). 
ANGPTL4 regulates the adhesion of melanoma 
cells to BEC
In order to disseminate the brain, melanoma cells 
must penetrate the brain endothelium. An initial step 
in this process is the adhesion of cancer cells to the 
endothelium [22]. We therfore evaluated changes in the 
capacity of cutaneous and MBM cells over-expressing 
ANGPTL4 to adhere to BEC. ANGPTL4hi cutaneous cells 
adhered better to BEC than the controls. On the other 
hand ANGPTL4hi MBM cells adhered less well to BEC 
than the corresponding CONpQC cells (P < 0.05) (Figure 
2F). We also determined the adherence capacity of GFP-
expressing ANGPTL4lo MBM cells and of CONsh cells to 
BEC. ANGPTL4lo MBM cells adhered better to BEC (P 
< 0.05) than their corresponding CONsh cells (Figure 2F). 
Taken together these results indicated that ANGPTL4 is a 
determinant of the adherence capacity of melanoma cells 
to BEC. Whereas ANGPTL4 promotes the adhesion of 
cutaneous cells to BEC it reduces the adhesion of MBM 
cells to BEC.
ANGPTL4 regulates melanoma cell 
transmigration through BEC
In a previous study we demonstrated that astrocytes 
have the capacity to chemo-attract melanoma cells thereby 
enhancing their ability to transmigrate through BEC [5]. 
We therefore evaluated whether ANGPTL4 affecs the 
transendothelial migration (TEM) of melanoma cells 
in a blood-brain barrier (BBB) model simulating the 
extravasation of melanoma cells through BEC towards 
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astrocytes. Figure 2H, 2I showed that ANGPTL4 over-
expression significantly enhanced the ability of m-Cherry 
labeled cutaneous melanoma cells to migrate towards 
astrocytes through BEC (P < 0.05). In contast, ANGPTL4 
over-expression attenuated the TEM of MBM cells (P < 
0.05). MBM cells in whom ANGPTL4 was knocked down 
Figure 3: Secretion of bioactive factors from melanoma cells is dependent on ANGPTL4 expression level. A.-C. 
Melanoma cells were cultured for 24 hrs, then starved for additional 24 hrs, to allow secretion of melanoma-soluble factors. CM was 
collected and added to BEC. Cell viability of BEC grown with CM of cutaneous CONpQC and ANGPTL4hi melanoma cells (A) or MBM 
CONpQC and ANGPTL4hi melanoma cells (B) was monitored after 24, 48 and 120 hrs. Cell viability of BEC grown with CM of MBM 
CONsh and ANGPTL4lo melanoma cells (C) was monitored after 72 hrs. Viability was determined using XTT-based assay. Absorbance at 
450 nm was determined for each well, and subtraction of nonspecific readings (measured at 630 nm) was calculated. The bars represent 
the average viability of the BEC grown with ANGPTL4hi or ANGPTL4lo melanoma CM relative to those grown in control melanoma CM 
+ SD in three independent experiments. Six replicates were performed in each experiment. *P < 0.05, **P < 0.005. D.-G. Melanoma 
cells were seeded for 24 hrs and then cultured in serum-free media for additional 24 hrs. CM were collected and subjected to gelatin 
and collagen zymography. (D, F) Images of one representative experiment out of three are presented. A ~66 kDa band indicating the 
active form of MMP-2 was observed. (E, G) The bars represent the average MMP-2 activity (pixel density) as measured by densitometry, 
normalized to control cells + SD in one measurement in three independent experiments . *P < 0.05, **P < 0.0.1, ***P < 0.005. H., I. BECs 
were treated with melanoma CM for 24 hours. Then, CLDN1 expression was analyzed using RT-qPCR and flow cytometry. (H) The bars 
represent the relative CLDN1 mRNA expression (normalized to RS9) compared to control cells + SD obtained in one measurement in 
least three independent experiments. *P < 0.05. (I) BEC were trypsinized and analyzed for CLDN1 expression using flow cytometry. Dot 
plot histogram comparing % CLDN1 positive BEC. Each dot represents the value obtained in a single independent experiment. The line 
represents the average value in each variant. **P < 0.01.
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(ANGPTL4lo cells) transmigrated more efficiently towards 
astrocytes through BEC than the corresponding CONsh 
cells (P < 0.05). 
The above results indicated that ANGPTL4 is 
functionally involved in the migration and TEM of 
melanoma cells. Whereas ANGPTL4 enhanced TEM of 
cutaneous melanoma cells through the blood brain barrier, 
it reduced TEM of the MBM cells through the blood 
brain barrier. The observation that ANGPTL4 influenced 
differentialy the ability of cutaneous and MBM cells to 
transmigrate through BEC layers may be due, at least in 
part, to the differential capacity of the two types of cells to 
adhere to brain-derived endothelium.
An alternative explanation is that when over-
expressed by the MBM cells, ANGPTL4 may increase 
the stability of endothelial junctions and thus increase 
endothelial cell barrier integrity, as demonstarted by 
Bouleti et al [23]. 
Secretion of factors that differentially modify the 
viability of BEC
Endothelial cell status and growth is a crucial factor 
in angiogenesis [24] whereby the cross-talk between tumor 
and endothelial cells contributes to these functions. To 
determine whether ANGPTL4 overexpressing melanoma 
cells differ from control cells in the ability to sustain the 
viability of BEC, BEC were treated with CM of CONpQC 
or ANGPTL4hi cutaneous and MBM cells. XTT assays 
indicated that CM of ANGPTL4hi cutaneous melanoma 
cells decreased the viability of BEC (compared to the 
viability of BEC exposed to CM of CONpQC melanoma 
cells), at 48 and 120 hrs of exposure (P < 0.05 and P < 
0.005, respectively) (Figure 3A). 
On the other hand at 120 hrs of exposure, CM of 
ANGPTL4hi MBM cells increased the viability of BEC 
Figure 4: ANGPTL4 alters the tumorigenic potential of melanoma cells. A. Volume of cutaneous tumors following subdermal 
implantation of CONpQC vs. ANGPTL4hi cutaneous cells. Tumor dimensions were measured using a caliper and volume was obtained as 
described in Materials and Methods. The average tumor volume + SEM is presented. *P < 0.05. B. Mice were weighed weekly following 
melanoma inoculation. The averege mouse weight + SD is presented. *P < 0.05. C. Melanoma cells were treated for 72 hrs with mouse 
BDF. Then, cells were trypsinized and cell death was determined by measuring DAPI incorporation. The bars represent the relative cell 
death of BDF treated cells compared to their controls + SEM obtained in one measurement in three independent experiments. *P < 0.05.
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compared to that of BEC exposed to CM of CONpQC cells 
(P < 0.05) (Figure 3B). 
Similar experiments were performed with CM of 
CONsh and ANGPTL4lo MBM cells. At 72 hrs of exposure 
the viability of BEC exposed to CM of ANGPTL4lo brain 
metastatic melanoma cells was lower than the viability of 
BEC exposed to CM of CONsh cells, (P < 0.05) (Figure 
3C). 
Taken together these results demonstrated that 
ANGPTL4 expressed by cutaneous melanoma cells 
induces or up-regulates secretion of soluble factors that 
inhibit BEC growth. In contrast ANGPTL4 in MBM 
cells induces or up-regulates secretion of soluble factors 
that promote BEC growth. This indicates the ANGPTL4 
expression effect is context dependent on the source of the 
melanoma cell.
Secretion of active matrix metalloproteinase-2 
(MMP-2) 
Invasive growth of cancer cells requires local 
proteolysis, which is mediated by locally secreted 
MMPs. These enzymes participate in ECM degradation 
during metastasis, and are essential for basement-
membrane penetration [25]. An increased expression of 
Figure 5: Proteomic expression analysis of ANGPTL4 high and low expressing cells. The expression of 305 proteins was 
examined using RPPA analysis in the ANGPTL4hi and ANGPTL4lo cells vs. their corresponding control cells. A., B., C. Comparisons were 
done for each pair of cells: (A) cutaneous ANGPTL4hi vs. CONpQC cells, (B) brain metastasizing ANGPTL4hi vs. CONpQC cells and (C) brain 
metastasizing ANGPTL4lo vs. CONsh cells. The tables show the normalized expression of differentially expressed proteins with FC < -1.25 
or FC>1.25. D., E. Venn diagrams were used to compare lists of differentially expressed proteins. (D) Proteins differentially expressed in 
both comparisons obtained in (A) and (B). (E) Proteins differentially expressed in both comparisons obtained in (B) and (C). F. Protein-
protein interactions of differentially expressed proteins with FC < -1.5 or FC>1.5 from all three comparisons. Circled in blue are proteins 
from comparison (A), circled in orange are proteins from comparison (B), and circled in green are proteins from comparison (C).
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MMP proteins, such as MMP-2 in tumor cells is often 
accompanied with increased invasiveness and metastasis, 
as well as with decrease in overall survival [26]. 
To determine if ANGPTL4 is involved in the 
regulation of MMP-2 activity, we performed gelatin and 
collagen zymography assays comparing cutaneous and 
MBM cells overexpressing ANGPTL4 (ANGPTL4hi) with 
appropriate control cells (CONpQC).
Whereas CONpQC and ANGPTL4hi cutaneous cells 
secreted higher levels of active collagen degrading MMP-
2 (P < 0.05) (Figure 3F, 3G), ANGPTL4hi MBM cells 
secreted significantly lower levels of active gelatin and 
collagen degrading MMP-2, than CONpQC cells (P < 0.01 
and P < 0.0005, respectively) (Figure 3D-3G).
We next examined if ANGPTL4 down-regulation 
in melanoma cells affects MMP-2 secretion. Gelatin 
zymography assays comparing the CONsh and ANGPTL4lo 
MBM cells showed that ANGPTL4lo MBM cells secreted 
higher levels of active gelatin degrading MMP-2 than 
CONsh cells (P < 0.005) (Figure 3D, 3E).
Taken together, these results imply that ANGPTL4 
inhibits MMP-2 activity in MBM cells, while it has an 
Figure 6: A proposed mechanism for ANGPTL4-mediated melanoma malignancy progression. A soluble factor in the 
microenvironment of the primary tumor transforming growth factor β1 (TGFβ1) induces the expression of ANGPTL4 in primary melanoma 
tumor cells. ANGPTL4 enhances their ability to migrate through extracellular matrix (ECM) components and to adhere and invade brain 
vasculature, for example by down-regulating the expression of cell-cell adhesion tight junction (TJ) molecules such as claudin-1 (CLDN1). 
Once arriving the brain, brain-derived soluble factors secreted by microglia, brain endothelial cells (BEC) and astrocytes, induce ANGPTL4 
expression by brain metastasizing cells, what contributes to different phenotypes, such as resistance against brain-derived cytotoxic factors, 
enhancement of BEC growth and induction of angiogenesis-related genes such as angiopoietin 1 (ANG1) (data not shown) in BEC subjected 
to factors released from brain metastasizing cells, expressing high ANGPTL4 levels.
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inducing effect on MMP-2 activity in the cutaneous cells. 
This suggests that ANGPTL4 contributes to melanoma cell 
invasion from the primary tumor to enhance metastatic 
spread. 
Secretion of factors that differentially decrease 
expression of CLDN1 by BEC
As ANGPTL4 reprograms endothelial permeability 
[15, 27] we asked if melanoma-associated ANGPTL4 
regulates either directly or indirectly the integrity of TJs 
in BEC. We utilized RT-qPCR and flow cytometry to 
measure the expression of CLDN1, a TJ protein known to 
be expressed on the BEC [10]. BEC were treated with CM 
of CONpQC or of ANGPTL4hi cutaneous and MBM cells. 
Figures 3H and 3I show that CM of ANGPTL4hi cutaneous 
cells down-regulated CLDN1 expression (P < 0.05), 
while CM of ANGPTL4hi MBM cells did not significantly 
alter the expression of this TJ protein, compared to the 
corresponding control cells. CM of ANGPTL4lo MBM 
cells also did not alter CLDN1 expression compared 
to the corresponding control cells. This suggests that 
ANGPTL4 contributes to melanoma cell passage through 
BBB junctions. 
In vivo functios: ANGPTL4 enhances melanoma 
tumorigenicity 
The question if and how ANGPTL4 is involved 
in the shaping of the in vivo malignancy phenotype of 
melanoma cells was examined. Local tumor formation 
was assessed in nude mice orthotropically inoculted with 
CONpQC or with ANGPTL4hi cutaneous human melanoma 
cells. 
An orthotopic inoculation of ANGPTL4hi cutaneous 
cells resulted in a significantly enhanced tumor growth 
compared to inoculation of CONpQC cutaneous cells (P < 
0.05) (Figure 4A). Mice inoculated with the ANGPTL4hi 
cutaneous cells weighed less than those inoculated with the 
CONpQC cutaneous cells, indicating the highly malignant 
phenotype of the desease (P < 0.05) (Figure 4B).
We next asked whether ANGPTL4 over-expression 
in cutaneous melanoma cells would influence the capacity 
of such cells to form spontaneous brain micro-metastasis. 
Nude mice were inoculated orthotopically with control 
(CONpQC) cutaneous melanoma cells or with cells 
overexpressing ANGPTL4 (ANGPTL4hi ). The mice were 
killed 65 days post inoculation and anaylzed, by RT-qPCR 
using human specific primers, for the presence of human 
melanoma micro-metastastais. No significant differences 
were found in the incidence of MBM between the two 
groups: CONpQC cells (brains of 10 mice out of 15 were 
positive for melanoma cells) and ANGPTL4hi cells (brains 
of 7 mice out of 16 were positive for melanoma cells) . 
The effects of BDF on melanoma cell viability is 
ANGPTL4-dependent 
Once extravasating to the target organ, metastasis 
propagation depends on the ability of disseminated 
tumor cells to survive and proliferate in their new 
microenvironment. Several studies showed that ANGPTL4 
is a regulator of cell proliferation [28]. We previously 
demonstrated that BDF promote the viability of cutaneous 
melanoma cells but induce cell death of MBM cells [29].
In order to find out whether ANGPTL4 levels play a 
role in the differential susceptability of the cutaneous and 
MBM cells to these soluble factors, we examined the effect 
of BDF on the viability of melanoma cells, expressing 
high or low levels of ANGPTL4. ANGPTL4hi and 
CONpQC cutaneous melanoma cells and ANGPTL4lo and 
CONsh MBM cells were treated with BDF or starvation 
medium (control) for 72 hrs. Cell death was determined by 
4’,6-Diamidino-2-phenylindole dihydrochloride (DAPI) 
incorporation measurement. Figure 4C demonstrates that 
BDF protected CONpQC cutaneous cells (low ANGPTL4 
expressing) from spontaneous cell death. On the other 
hand BDF induced cytotoxicity in ANGPTL4hi cutaneous 
cells. These experiments lead us to conclude that a high 
expression of ANGPTL4 in the cutaneous cells sensitizes 
these melanoma cells to cytotoxicity mediated by BDF.
BDF treatment of MBM cells expressing relatively 
high levels of endogenous ANGPTL4 (CONsh) induced 
cell death. Treating MBM cells expressing reduced levels 
of ANGPTL4 (ANGPTL4lo) with BDF, resulted in further 
induction of cell death. Expression of ANGPTL4 in the 
MBM cells protects these melanoma cells from death 
exerted by BDF, increasing their sustainability in the brain 
microenvironment.
Reverse Phase Protein Array (RPPA) analysis 
of melanoma cells differentially expressing 
ANGPTL4
In the next set of experiments we examined the 
effect of ANGPTL4 over-expression or knock-down on 
protein expression profile in melanoma cells. To this end 
we compared RPPA data of ANGPTL4 overexpressing 
(ANGPTL4hi) cutaneous melanoma cells and MBM 
cells with the corresponding control (CONpQC) cells. For 
each pair of cells we established a list of proteins which 
were differentially expressed in a FC < -1.25 or FC>1.25 
(Figure 5A, 5B, respectively). Identifying the differentially 
expressed proteins may highlight the mechanism by 
which ANGPTL4 regulates the malignancy phenotype of 
melanoma cells.
We observed 27 proteins that were differentially 
expressed in the cutaneous melanoma cell pair (YDFR.C-
ANGPTL4hi vs. YDFR.C-CONpQC) comparison (Figure 
5A). This list of proteins includes CD171 (L1CAM), 
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which is up-regulated (FC=1.6) in ANGPTL4hi cells. 
L1CAM has a role in metastatic cell spreading along 
brain capillaries and in metastatic outgrowth [30]. Another 
up-regulated protein is monocarboxylate transporter 4 
(MCT4; FC=2.01), a lactate transporter, whose expression 
was found to be increased with melanoma progression 
from nevi to advanced metastatic disease [31].
We observed 25 proteins that were differentially 
expressed in the MBM cell pair (YDFR.CB3-ANGPTL4hi 
vs. YDFR.CB3-CONpQC) (Figure 5B). This list of proteins 
includes the von Hippel-Lindau tumor suppressor (VHL), 
down-regulated (FC=-1.43) in the ANGPTL4hi cells.
RPPA analysis was also performed to establish the 
effect of ANGPTL4 knock-down on protein expression 
profile of the MBM cell pair (YDFR.CB2-ANGPTL4lo 
vs. YDFR.CB2-CONsh). RPPA analysis yielded a list of 
22 proteins that were differentially expressed in a FC < 
-1.25 or FC>1.25 (Figure 5C). This list of proteins include 
connexin-43 (FC=-1.34), whose inhibition promotes 
melanoma cell proliferation [32]. 
Venn diagram analysis was performed to provide 
a list of shared differentially expressed proteins that are 
altered in the cutaneous and MBM ANGPTL4 over-
expressing cells compared to their controls (Figure 
5D). 6 proteins were identified in both lists: ALDH1A1, 
β-catenin, E-Cadherin, Gab2, Stat5a and vimentin. These 
proteins are all either up-stream or down-stream to 
epithelial to mesenchymal transition (EMT) regulators in 
tumor cells [33-36]. This may imply that EMT constitutes 
a mechanism by which ANGPTL4 is involved in 
melanoma progression. Most interesting proteins are those 
that show an opposite trend of alteration in the cutaneous 
vs. the MBM pairs, in correspondence to the opposite pro/
anti-malignancy effects of ANGPTL4 over-expression 
observed in the experiments above. Five of these proteins: 
E-Cadherin, GRB2-associated-binding protein 2 (Gab2), 
Stat5a, vimentin, and β-catenin were differentailly 
expressed in the two comparisons in an opposite manner. 
Venn diagram analysis was also performed to 
provide a list of shared differentially expressed proteins 
that are altered following ANGPTL4 over-expression 
and knock-down in the metastatic variants (Figure 5E). 
Six proteins appeared in both comparisons: ACC_pS79, 
ALDH1A1, CDK1, E-Cadherin, PDGFR-beta, and 
Vimentin. PDGFR-beta was differentially expressed in 
the two comparisons in an opposite manner. These results 
imply again that EMT may be involved in ANGPTL4-
mediated melanoma progression, due to the observed 
changes in the expression of these proteins, all of which 
are either up-stream or down-stream to EMT regulation in 
tumor cells [37-39].
Network of protein interactions was created for 
proteins differentially expressed in a FC < -1.5 or FC>1.5 
from the three comparisons using STRING (Figure 5F). 
The biological processes ascribed to these differentially 
expressed proteins include: kinase activity, metabolism, 
proliferation and apoptosis, all of which have relevance 
in metastasis.
DISCUSSION
Metastasis is the major cause leading to death 
from cancer. Treating metastasis is complex since 
frequently it has already occurred by the time the disease 
was diagnosed [40]. The growth and progression of 
metastasis is dependent on the tumor autonomous traits 
as well as on the interactions of the cancer cells with 
microenvironmental cells in their vicinity and with soluble 
factors released or secreted by them [40-45]. However, 
relatively little information exists on the interaction of 
constituent normal brain cells of tumor microenvironment 
with brain metastasis. Understanding the molecular basis 
for the spread of melanoma to the brain and the cellular 
interactions within the microenvironment is necessary 
for the development of novel therapeutic and prognostic 
solutions for this disease.
This study showed that ANGPTL4 is more highly 
expressed in MBM cells than in corresponding cutaneous 
melanoma cells in human MBM models as well as in 
clinical samples. Interestingly, MBM exhibited higher 
expression of ANGPTL4 than paired LNM. This result 
emphasizes the importance and selectivity of ANGPTL4 
for metastasis propagation in the brain. 
We have demonstrated that soluble factors in the 
brain microenvironment, including those secreted by 
microglia, astrocytes and brain endothelium, up-regulate 
ANGPTL4 expression. The exact soluble components 
of the brain which are responsible for ANGPTL4 up-
regulation were not yet characterized. One of the candidate 
factors is TGFβ1, known to be up-regulated in the injured 
or inflamed brain [46-49].
The increase in ANGPTL4 expression, may, at 
least in part, be attributed to TGFβ1 stimulation. Cancer 
cells, including melanomas, tend to selectively utilize the 
beneficial functions of TGFβ signal transduction, including 
ANGPTL4 up-regulation (via the Smad signaling 
pathway), while eliminating the tumor suppressor function 
downstream to TGFβ [50, 51]. In ER negative breast 
tumors, TGFβ induces ANGPTL4 expression, thereby 
priming tumor cells for lung metastasis. This is enabled 
by microenvironmental TGFβ that induces or upregulates 
ANGPTL4 expression in disseminating tumor cells on 
their way to secondary metastatic sites. The upregulated 
ANGPTL4 enables tumor cells to disrupt vascular 
endothelial junctions when arriving the lung capillaries, 
thereby facilitating their trans-endothelial passage [50, 
51]. A similar mechanism may operate in the case of 
MBM, as we have demonstrated that ANGPTL4 increases 
the ability of melanoma cells to penetrate brain endothelial 
cell monolayer.
To investigate the involvement of ANGPTL4 in 
melanoma malignancy, we have established cutaneous 
Oncotarget75789www.impactjournals.com/oncotarget
and MBM cells in which ANGPTL4 is overexpressed and 
MBM cells in whom ANGPTL4 is knocked-down. 
The results demonstrated that like certain other 
genes [52, 53], ANGPTL4 plays a yin-yang role depending 
on tumor stage; it promotes malignancy of cutaneous 
melanoma cells and ameliorates the malignant phenotype 
of brain-metastasizing cells.
In the early phases of the metastatic cascade, 
when the tumor cells are still outside the brain 
microenvironment, over-expression of ANGPTL4 in 
the cutaneous cells promoted characteristics that would 
enable their invasion to the target organ, the brain 
microenvironment. These malignancy-promoting activities 
included increase in the volume of the primary tumor, 
increased MMP activity, promoting migration through 
ECM, adhesion to BEC and penetration through a brain 
endothelial layer towards astrocytes. Stimulation of 
BEC with CM of ANGPTL4 over-expressing cutaneous 
melanoma cells down-regulated the expression of CLDN1, 
a TJ protein involved in cell adhesion. 
Un-expectedly and in contrast to the enhanced 
ability of ANGPTL4 overexpressing cutaneous cells to 
form local tumors, their ability to form brain metastasis 
was not promoted. Based on the results summarized 
above, the following scenario may account for these 
seemingly contradictory findings: In view of the fact 
that ANGPTL4 overexpression enhances migration and 
transmigration of cutaneous melanoma cells through the 
BBB, such cells would preferentially localize in the brain. 
However ANGPTL4 overexpressing cutaneous melanoma 
cells are sensitive to the cytotoxic activity of BDF which 
would diminish metastasis. 
BDF, as described in the Materials and Methods 
section is a mixture of soluble factors released from 
the brain of BALB/c mice incubated for 24 or 48 hrs 
(depending on the experiment) at 37°C. This method of 
preparation was developed by Maman et al. from our 
laboratory [54, 55] who prepared lung derived factors 
which restrained the proliferation of lung metastasis. 
Preliminary, unpublished experiments indicated that the 
BDF is a protein with a molecular weight above 3.5kDa. 
In the future we plan to identify the active factors in 
the BDF, that affect melanoma cell viability and other 
observed phenomena (i.e. ANGPTL4 expression). 
Over-expression of ANGPTL4 in the MBM cells 
moderates the malignancy-promoting activities. Down-
regulation of ANGPTL4 in MBM cells yielded, in 
general, compatible results to those reported above: The 
malignancy phenotype of these cells was promoted. MBM 
cells with down-regulated levels of ANGPTL4 adhered 
better to BEC, secreted higher levels of active MMP-2 and 
penetrated more efficiently through the BBB. 
The scenario taking place at later stages of 
metastasis when melanoma cells have already penetrated 
the tumor microenvironment of the brain is different. 
Cancer cells must be able to survive and proliferate in 
order to establish the metastatic foci. Cells should have 
the ability to avoid cell death and to promote angiogenesis, 
necessary for nutrient and oxygen supply. For angiogenesis 
to occur, endothelial cells must migrate and proliferate at 
the distant metastatic site [24].
MBM cells, expressing high levels of endogenous 
ANGPTL4 (CONsh cells), are less sensitive to the viability 
restraining function of BDF then the same cells with 
down-regulated ANGPTL4 expression (ANGPTL4lo 
cells). ANGPTL4 may thus protect such cells from BDF 
mediated death. 
Soluble factors from MBM cells over-expressing 
ANGPTL4 had a growth promoting effect on BEC. Down-
regulation of ANGPTL4 in the MBM cells resulted in 
reduced BEC viability. Therefore, ANGPTL4 expressed 
by MBM cells may support angiogenesis in the brain. This 
possibility will be further investigated in the future.
The experiments described above demonstrate that 
ANGPTL4 expression level has a significant involvement 
in melanoma-BEC interactions, and that autocrine effects 
of ANGPTL4 on melanoma cells may result in paracrine 
effects on BEC. 
As indicated above, TGFβ1 induced ANGPTL4 
expression in melanoma cells. Interestingly, RPPA analysis 
of high vs. low ANGPTL4 expressing melanoma cells 
demonstrated that most differentially expressed proteins 
are either up-stream or down-stream of the EMT cascade, 
which is classically controlled by the TGFβ pathway. 
Further investigation is aimed to elucidate the mechanism 
by which ANGPTL4 regulates these proteins. It is not 
unlikely that similarly to how ANGPTL2 and TGFβ1 
positively increase the expression of each other in chronic 
kidney disease [56], ANGPTL4 and TGFβ1 employ such 
reciprocal effects on each other expression.
Taken together our study demonstrates that 
whereas ANGPTL4 promotes the malignancy phenotype 
of cutaneous melanoma cells in early stages of brain 
metastasis, it ameliorates the malignancy phenotype of 
MBM cells in the later stages of brain metastasis, when 
the brain tumor microenvironment plays a significant 
functional role in disease progression. The data presented 
is in agreement with studies showing that the expression 
and roles of ANGPTL4 are context and tumor stage 
dependent, and that ANGPTL4 has a diverse role in 
metastasis [34]. 
We propose a mechanism for brain metastasis 
(illustrated in Figure 6) whereby a soluble factor in the 
microenvironment of the primary tumor (e.g. TGFβ1) 
induces the expression of intracellular or extracellular 
proteins (e.g. ANGPTL4) in cells of the primary tumor. 
These cells are able to migrate through ECM, adhere 
to and invade brain vasculature, for example by down-
regulating the expression of cell-cell adhesion TJ 
molecules such as CLDN1 [57, 58]. Once in the brain, 
angiogenesis promotion, endothelial proliferation 
and survival may have a higher priority rather than 
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characteristics such as adhesion and invasion. Therefore 
in MBM cells, high expression of ANGPTL4 (induced by 
brain-derived soluble factors) may contribute to different 
phenotypes, such as resistance against brain-derived 
cytotoxic factors, enhancement of BEC growth and 
induction of angiogenesis-related genes such as ANG1 
(data not shown) in BEC subjected to factors released 
from MBM cells which express high levels of ANGPTL4. 
MATERIALS AND METHODS
Animals
Male BALB/c mice were purchased from Tel Aviv 
University animal facility. Male athymic nude mice 
(BALB/c background) were purchased from Harlan 
Laboratories Limited (Israel). The mice were housed 
and maintained in laminar flow cabinets under specific 
pathogen-free conditions in the animal quarters of Tel-
Aviv University and in accordance with current regulations 
and standards of the Tel-Aviv University Institutional 
Animal Care and Use Committee. The mice were used 
when they were 7-8 weeks old.
Cell culture
The production and maintenance of cutaneous 
human melanoma variant (YDFR.C) and MBM variants 
(YDFR.CB2 and YDFR.CB3) were described previously 
[8]. 
Novel xenograft models were obtained from the 
parental cell lines UCLA-SO-M12, UCLA-SO-M16 and 
DP-0574-Me (JWCI) as we described previously for 
the YDFR cells [8], and consist of cutaneous variants 
(C variants) and brain macro-metastatic variants (CB1 
and CB2 variants; the number represents the number of 
cycles of re-inoculation into the left ventricle of the heart 
as described previously [8]). Human embryonic kidney 
293T cells were maintained as described previously [10]. 
Immortalized human brain microvascular endothelial cells 
(hCMEC/D3) were kindly provided by Dr. Clara Nahmias 
and Prof. Pierre-Olivier Couraud (Inserm, U1016, 
Institut Cochin, Paris, France) and were maintained as 
described by Weksler et al [59]. Human astrocytes were 
maintained as described previously [5]. Immortalized 
human microglia-SV40 cell line was purchased from 
ABM (ABM, Milton, Canada) and were maintained on 
100μg/ml collagen I, rat tail (BD Biosciences, Bedford, 
MA, USA) in 10% fetal calf serum (FCS) supplemented 
Prigrow III medium (ABM).
0.5% FCS supplemented medium was used for 
starvation in all the experiments, unless indicated 
otherwise. Cells were routinely cultured in humidified air 
with 5% CO2 at 37°C. 
Western blotting
Cells were plated in growth medium for 24 hrs. 
For the detection of secreted ANGPTL4, supernatants 
were collected, centrifuged at 1400 rpm for 5 min and 
filtered (0.45µm). For the detection of intracellular 
ANGPTL4, the plated cells were washed twice with 
ice-cold PBSX1 and lysed (20mM Tris pH 8, 250mM 
NaCl, 0.5% Nonident p-40 (NP-40), 5mM EDTA pH 
8, 4mM EGTA pH 8, 20mM sodium phosphate pH 7.6, 
3mM β glycerol phosphate, 2mM sodium orthovanadate 
(Na3VO4), 5mM NaF, 10mM sodium pyrophosphate 
pH 7.6, 2 µg/ml aprotinin, 2 µg/ml leupeptin and 1mM 
phenylmethylsulfonyl (PMSF) supplemented with DDW). 
Cell lysates were incubated for 20 min on ice and cleared 
by centrifuging at 16,000g for 20 min at 4°C. Pierce 
BCA protein assay kit (Thermo Scientific, Rockford, IL, 
USA) was used to determine protein concentration. After 
the addition of Laemmli sample buffer, the lysates or 
supernatants were resolved on SDS-PAGE, and transferred 
onto nitrocellulose membrane. The total amount of protein 
in the lanes was assessed by Ponceau staining prior to 
blocking of the membrane. The membranes were blocked 
at room temperature with 3% BSA diluted in TBS-Tween 
for 1 hr. For detection of the target proteins, membranes 
were incubated with relevant primary antibodies: Anti-
human ANGPTL4 antibody (Ab) (1:350, R&D Systems, 
Inc., Minneapolis, MA, USA) and rabbit polyclonal to beta 
Tubulin (1:500, Abcam, Cambridge, UK). Horseradish 
peroxidase-conjugated donkey anti-goat or goat anti-rabbit 
(1:10000, Jackson ImmunoResearch Laboratories, West 
Grove, PA, USA) were used as secondary Ab. 
The bands were visualized by chemoluminescence-
ECL reactions and autoradiography by exposure to Fuji 
film. The amount of the relevant protein in the lanes was 
estimated by densitometry using Quantity One Image 
software.
Flow cytometry
CLDN1 expression was analyzed by monoclonal 
anti-human CLDN1 Ab (1μg/sample, R&D Systems), 
using flow cytometry as described previously [9]. 
Fluorescein isothiocyanate (FITC)-conjugated goat anti-
rat IgG (1:50, Jackson ImmunoResearch Laboratories) 
was used as secondary Ab. 
Antigen expression was determined using Becton 
Dickinson FACSort (Becton Dickinson Mountain View, 
CA, USA) and CellQuest software. Dead cells were gated 
out from the analysis.
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Immunohistochemistry (IHC) 
Cutaneous melanoma patients were included in 
the study at John Wayne Cancer Institute under the 
MORD-RTPCR-0995 protocol approved by the Western 
Institutional Review Board (WIRB Protocol #20072107). 
Informed consent was obtained from all subjects and the 
experiments were performed according to the principles 
set out in the WMA Declaration of Helsinki and the NIH 
Belmont Report. Tissue specimens were de-identified and 
coded according to HIPAA recommendations to ensure the 
confidentiality of the patients.
IHC was performed on 5µm human melanoma 
sections. Slides were deparaffinized, rehydrated, and 
then antigen retrieval was performed using 10mM 
sodium citrate buffer (pH 6.0) in a boiling water bath 
for 20 min. The sections were then incubated in 10g/L 
trichloroisocyanuric acid (Sigma-Aldrich) solution for 
30 min at RT to bleach melanin [60]. After rinse with tap 
water, endogenous peroxidase was blocked with hydrogen 
peroxide for 10 min and nonspecific binding was blocked 
with Protein Block serum-free solution (Dako, Glostrup, 
Denmark) for 10 min. The sections were incubated 
overnight with the anti-ANGPTL4 rabbit polyclonal Ab 
(Proteintech Group, Inc, Rosemont, IL, USA) at a dilution 
of 1:100 in a 4°C humidified chamber. Visualization was 
performed using LSAB2 system-HRP (Dako) and Liquid 
DAB+ Substrate Chromogen System (Dako) according 
to the manufacturer’s instructions. After visualization, 
the sections were counterstained with Gill’s hematoxylin 
(Sigma-Aldrich) for 1.5 min at RT, dehydrated, and 
mounted. After the IHC, photographs were taken using a 
Nikon Eclipse Ti microscope and NIS elements software 
(Nikon, Melville, NY, USA) and analyzed by ImageJ 
software (National Institute of Health, version 1.50i). 
The expression of ANGPTL4 was quantified using H 
score system [61], which considers both the intensity and 
percentage of positive cells. The score was calculated 
using the formula 1x(% of 1+ cells)+2x(% of 2+ 
cells)+3x(% of 3+ cells).
Reverse phase protein array (RPPA) 
1X106 melanoma cells were seeded for 24 hrs. 
Then cells were harvested by Trypsin EDTA (Biological 
Industries). Cell pellet was washed twice with phosphate-
buffered saline (PBS) and lysed (1% Triton X-100, 
50mM HEPES, pH 7.4, 150mM NaCl, 1.5mM MgCl2, 
1mM EGTA, 100mM NaF, 10mM Na pyrophosphate, 
1mM Na3VO4, 10% glycerol, protease and phosphatase 
inhibitors). Protein concentration was adjusted to 
1-1.5µg/µl and denatured by 1% SDS. Cell lysates were 
two-fold-serial diluted for 5 dilutions (from undiluted 
to 1:16 dilution) and arrayed on nitrocellulose-coated 
slides in 11x11 format. Samples were probed with Ab 
by CSA amplification approach and visualized by DAB 
colorimetric reaction. 
Slides were scanned on a flatbed scanner to 
produce 16-bit tiff images. Spots from tiff images were 
identified and the density was quantified by Array-Pro 
Analyzer. Relative protein levels for each sample were 
determined by interpolation of each dilution curve from 
the “standard curve” (supercurve) of the slide (Ab). 
Supercurve is constructed by a script in R written by 
Bioinformatics (“Supercurve Fitting” developed by the 
Department of Bioinformatics and Computational Biology 
in MD Anderson Cancer Center, http://bioinformatics.
mdanderson.org/Software/supercurve). Each dilution 
curve was fitted with a logistic model. This fits a single 
curve using all the samples (i.e., dilution series) on a slide 
with the signal intensity as the response variable and the 
dilution steps are independent variable. The fitted curve 
(“supercurve”) was plotted with the signal intensities on 
the Y-axis and the relative log2 concentration of each 
protein on the X-axis using the non-parametric, monotone 
increasing B-spline model. During the process, the raw 
spot intensity data were adjusted to correct spatial bias 
before model fitting. A QC metric was returned for each 
slide to help determine the quality of the slide: if the score 
is less than 0.8 on a 0-1 scale, the slide was dropped. In 
most cases, the staining was repeated to obtain a high 
quality score. The protein concentrations of each set of 
slides were then normalized by median polish, which was 
corrected across samples by the linear expression values 
using the median expression levels of all Ab experiments 
to calculate a loading correction factor for each sample.
These values (given as log2 values) are defined as 
Supercurve Log2 (Raw) values. All the data points were 
normalized for protein loading and transformed to linear 
values. 
The identification of proteins differentially 
expressed in the different comparisons of overexpression/
down-regulation compared to control (fold change (FC < 
-1.25 or FC >1.25) was performed. 
Venny tool was used to compare between 
differentially expressed genelists (http://bioinfogp.cnb.
csic.es/tools/venny/). 
Network of protein interactions between 
differentially expressed proteins (FC < -1.5 or FC>1.5) 
was generated using STRING (http://string-db.org).
Reverse transcription quantitative real-time PCR 
(RT-qPCR)
cDNA extraction and RT-qPCR were performed 
as described previously [8]. For mRNA amplification, 
primers were designed based on the GenBank 





5‘ATACCATGCTGTGGCAACTAA-3‘; human RS9: 
S-5‘-CGGAGACCCTTCGAGAAATCT-3‘, AS-5‘-
GCCCATACTCGCCGATCA-3‘. Amplification reactions 
were performed with SYBR Green I (Thermo fisher 
scientific, ABgene, Germany) in duplicates in Rotor-gene 
6000TM (Corbett life science, Australia) and Rotor-Gene 
Q software. PCR amplification was performed over 40 
cycles (95ºC for 15 sec, 59ºC for 20 sec, 72ºC for 15 sec).
Construction of the expression vector and stable 
over-expression of ANGPTL4
The over-expression construct of human ANGPTL4 
(NM_139314) was created by PCR amplification 
of genomic DNA by Phusion® High-Fidelity DNA 
polymerase (Thermo Fisher Scientific), using the 
following primers (designed based on the GenBank 
Nucleotide Database of the NCBI website): ANGPTL4: 
S-5’-TCTCTCACCGGGTATGAGCGGTGCTCCGACG
GCC-3’, AS-5’-GTGTCTTAATTAACTAGGAGGCTG
CCTCTGCTGC-3’ The generated fragment was digested 
with AgeI and PacI and ligated into the corresponding 
sites of pQCXIP vector (Clontech Laboratories, Inc., 
Mountain View, CA, USA). PCR products of ANGPTL4 
were sequenced and found to be identical to the published 
sequence. Production of infectious viruses and melanoma 
infection were performed as described previously [10]. 
To produce mCherry expressing cells, melanoma 
cells were similarly transduced with a pQCXIN-mCherry 
plasmid and were selected using 800μg/ml G418 Sulfate 
(A.G. Scientific, Inc., San Diego, CA, USA). 
ANGPTL4 down-regulation in melanoma cells
The down-regulation of ANGPTL4 was established 
using a mixture of four different pGIPZ vectors 
containing shRNA sequences targeting ANGPTL4 
mRNA (NM_139314) (RHS4430-200184490, RHS4430-
200245716, RHS4430-200246249 and RHS4430-
200243106; Thermo Fisher Scientific). A sh-non-silencing 
pGIPZ vector (RHS4531) was used as a negative control.
To produce the infectious viruses, the 293T 
packaging cell line was co-transfected using the 
calcium phosphate method with the lentiviral plasmids 
shANGPTL4-pGIPZ or the sh-non-silencing-pGIPZ, 
packaging plasmid pCMV∆R8.2 and envelope plasmid 
pVSV-G. After 48 hrs, the virus particles in the medium 
were collected and filtered (0.45μm; Whatman GmbH). 
Melanoma cells, seeded 24 hrs before infection, 
were infected in the presence of 8µg/ml polybrene and 
the virus-containing medium, which was afterwards 
replaced with fresh growth medium. After 72 hrs 2µg/
ml puromycin (InvivoGen, San Diego, CA, USA) was 
added for additional 7 days to select stably infected cell 
populations. After selection, puromycin was continuously 
added to the culture.
Preparation of melanoma or brain cell CM
Melanoma, microglia, astrocyte or BEC were 
cultured for 24 hrs. The cells were washed and starved for 
24 hrs. CM was collected, centrifuged for 5 min at 1400 
rpm and filtered (0.45μm).
Stimulation of melanoma cells with BDF for cell 
viability analysis
Brains of BALB/c mice were harvested, minced 
to pieces in starvation medium and put on non-tissue 
culture dishes in 10ml of the same media for 48 hrs at 
37°C, to allow the secretion of BDF. Then, supernatantes 
were collected, centrifuged for 5 min at 1400 rpm, 
filtered (0.45μm) and further diluted to a concentration of 
1.6mg/ml. Melanoma cells, cultured 24 hrs prior to the 
experiment, were treated with BDF for 72 hrs at 37°C. 
Starvation medium was added to control melanoma cells. 
After 72 hrs, cell death was determined following the 
addition of 5µl of 5mg/ml DAPI using S1000Exi flow 
cytometer (stratedigm, San Jose, CA, USA) and FlowJo 
software. 
Stimulation of melanoma cells with tumor growth 
factor β1 (TGFβ1) 
Melanoma cells were starved for 1 hr, then 
stimulated for 4 hrs with 5ng/ml [62] recombinant human 
TGFβ1 (PeproTech Inc., Rocky Hill, NJ, USA) at 37°C. 
Control cells were treated with the same medium without 
TGFβ1.
Stimulation of melanoma cells with BDF for 
ANGPTL4 expression analysis
BDF were prepared as mentioned above in 0.5% 
bovine serum albumin (BSA) supplemented RPMI-
1640, after 24 hrs of incubation at 37°C. Melanoma cells, 
cultured 24 hrs prior to the experiment, were treated with 
BDF for 24 hrs at 37°C. 0.5% BSA supplemented RPMI-
1640 was added to control cells. Cells were analyzed for 
ANGPTL4 expression using RT-qPCR.
Viability assay (XTT)
Cell Proliferation Kit (XTT, Biological industries) 
was used according to the manufactures’ instructions. To 
obtain the relative cell viability, the optical density (OD) 
of the treated cells (in each time point) was divided by the 
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OD of the non-treated cells at the same time point of the 
experiment.
Adhesion to BEC
Adhesion of melanoma cells to BEC was performed 
as described previously [10]. Adhesion of GFP-expressing 
cells was measured at wavelength of 490/530. Adhesion 
of mCherry-expressing cells was measured at wavelength 
of 590/645. To obtain the cell relative adhesion capacity, 
the OD of the adherent cells was divided by the OD of the 
total cells plated. 
Migration through extracellular matrix
1X105 melanoma cells were loaded onto collagen-
coated transwell inserts (8μm; Corning Costar Corp., 
New York, NY, USA) and allowed to migrate for 24 hrs 
towards starvation medium. Then, the upper side of the 
apical chamber was scraped gently with cotton swab, to 
remove non-migrating cells. Cells at the bottom side of 
the transwell inserts were fixed with ice-cold methanol for 
5 minutes. Migrating cells were stained with Dif-stain Kit 
(Kaltek, Padova, Italy), according to the manufacturer‘s 
instructions. The number of melanoma cells transmigrating 
to the underside of the membrane was determined in each 
experiment by counting at least five independent fields 
in duplicates using OlympusIX53 inverted microscope 
(Olympus, Center Valley, PA, USA).
Transendothelial migration through a BBB model
In vitro BBB models consisting of BEC co-cultured 
with astrocytes are utilized for studying the properties of 
the BBB [63].
5X104 BEC were loaded onto collagen-coated 
transwell inserts (8μm; Corning Costar Corp.) and allowed 
to create a monolayer for 48 hrs (illustrated in Figure 2G). 
Simultaneously, 5X104 astrocytes were separately plated 
at the bottom of Poly-L-Lysine-coated 24-wells. 24 hrs 
later astrocytes were washed and starved for another 
24 hrs, to allow secretion of astrocyte-derived soluble 
factors into the medium. 48 hrs after seeding of BEC 
and astrocytes, 1X105 mCherry-expressing melanoma 
cells were loaded onto the endothelial monolayer and 
allowed to migrate towards the astrocytes for 24 hrs. 
Then, the upper side of the apical chamber was scraped 
gently with cotton swab, to remove non-migrating cells. 
Cells at the bottom side of the transwell inserts were 
fixed with 4% paraformaldehyde and mounted with DAPI 
Fluoromount-G (SouthernBiotech, Birmingham, AL, 
USA). The number of melanoma cells transmigrating 
to the underside of the membrane was determined in 
each experiment by counting at least five independent 
fields under fluorescence microscopy in duplicates using 
OlympusIX53 inverted microscope (Olympus). 
Gelatin zymography analysis
4.5X105 melanoma cells were plated in 24-well 
plates for 24 hrs, then growth medium was removed 
and replaced by 500µl serum-free RPMI-1640 medium 
for additional 24 hrs. To determine MMP-2 activity, 
CM was collected and subjected to gelatin and collagen 
zymography assay as described previously [64].
Orthotopic inoculation of tumor cells and in vivo 
tumorigenicity and metastasis formation assays
To generate subcutaneous tumors, 1X106 cells in 
100μl of 5% FCS supplemented RPMI-1640 medium were 
inoculated subdermally into the right thigh of male nude-
BALB/c mice.
To test the tumorigenic properties of derived cell 
lines, subcutaneous tumors were measured once a week 
using a caliper. Tumor volume was obtained by the 
ellipsoid volume calculation formula 0.5X(lengthXwidth2) 
[65, 66]. Mice were weighed weekly. Mice were 
killed when moribund, and brains were harvested and 
immediately frozen and stored at -70°C, until used 
for RNA extraction. Detection of human cells (micro-
metastases) in mouse brain by RT-qPCR was performed 
as described previously [8].
Statistical analysis
Paired or unpaired Student t test was used to 
compare in vitro and in vivo results. 
For the IHC experiments, statistical differences on 
the H-score values were analysed by using the Kruskal-
Wallis test among the groups. Additionally, the Steel-
Dwass method was used to further compare between 
groups that were considered statistically significant. The 
statistical analyses were performed with EZR (Saitama 
Medical Centre, Jichi Medical University, Saitama, Japan, 
version 1.32), a graphical user interface for R (The R 
Foundation for Statistical Computing, Vienna, Austria).
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